Nationwide surveillance of antibacterial susceptibility in bacterial respiratory pathogens in Japan, 2022-2023

Issei Tokimatsu¹, Yuji Fujikura², Tetsuya Matsumoto³, Hiroki Tsukada⁴, Makoto Miki⁵, Yoshitomo Morinaga³, Junko Sato³, Satoshi Takahashi³, Naoki Hasegawa⁶, Hideji Yanagisawa⁷, Takaaki Sasaki⁸, Natsuko Tamaru⁸, Hiroshi Takahashi⁹, Daisuke Kurai¹⁰, Yoshifumi Uwamino¹¹, Makoto Kudo¹², Yuko Nagano¹³, Akira Youkou¹⁴, Satoshi Kawasaki¹⁵, Atsushi Tabata¹⁵, Yoshitsugu Iinuma¹⁶, Yuki Miyajima¹⁷, Yoshihiro Yamamoto¹⁷, Hiroshige Mikamo¹⁸, Hirotoshi Ohta¹⁸, Takaya Maruyama¹⁹, Atsushi Nakamura²⁰, Michinori Shirano²¹, Yasunori Fujikawa²¹, Tatsuya Fukumori²², Taku Ogawa²³, Hiroshi Kakeya²⁴, Koichiro Yoshida²⁵, Koji Utsunomiya²⁵, Yoshihiro Kobashi²⁶, Hirokazu Tokuyasu²⁷, Satoshi Hino²⁷, Kazuhiro Yatera²⁸, Masaki Fujita²⁹, Katsunori Yanagihara³⁰, Kosuke Kosai³⁰, Kazufumi Hiramatsu³¹, Hiroyuki Muranaka³², Takashi Shinzato³³

Affiliations

¹ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Showa Medical University School of Medicine, Tokyo, Japan. Electronic address: issei@med.showa-u.ac.jp.
² The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; National Defense Medical College Hospital, Saitama, Japan.
³ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
⁴ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; The Jikei University Kashiwa Hospital, Chiba, Japan.
⁵ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Japanese Red Cross Sendai Hospital, Miyagi, Japan.
⁶ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Keio University Hospital, Tokyo, Japan.
⁷ MicroSKY Lab, Inc, Tokyo, Japan.
⁸ Asahikawa Medical University Hospital, Hokkaido, Japan.
⁹ Saka General Hospital, Miyagi, Japan.
¹⁰ Kyorin University Hospital, Tokyo, Japan.
¹¹ Keio University Hospital, Tokyo, Japan.
¹² Yokohama City University Medical Center, Kanagawa, Japan.
¹³ The Jikei University Kashiwa Hospital, Chiba, Japan.
¹⁴ Niigata City General Hospital, Niigata, Japan.
¹⁵ Shinrakuen Hospital, Niigata, Japan.
¹⁶ Kanazawa Medical University, Ishikawa, Japan.
¹⁷ Toyama University Hospital, Toyama, Japan.
¹⁸ Aichi Medical University Hospital, Aichi, Japan.
¹⁹ Mie Prefectural Ichishi Hospital, Mie, Japan.
²⁰ Nagoya City University Hospital, Aichi, Japan.
²¹ Osaka City General Hospital, Osaka, Japan.
²² Nara Medical University Hospital, Nara, Japan.
²³ Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
²⁴ Osaka Metropolitan University Hospital, Osaka, Japan.
²⁵ Kindai University Hospital, Osaka, Japan.
²⁶ Kawasaki Medical School Hospital, Okayama, Japan.
²⁷ Matsue Red Cross Hospital, Shimane, Japan.
²⁸ Hospital of the University of the Occupational and Environmental Health, Japan, Fukuoka, Japan.
²⁹ Fukuoka University Hospital, Fukuoka, Japan.
³⁰ Nagasaki University Hospital, Nagasaki, Japan.
³¹ Oita University Hospital, Oita, Japan.
³² Saiseikai Kumamoto Hospital, Kumamoto, Japan.
³³ Nakagami Hospital, Okinawa, Japan.

PMID: 40774506
DOI: 10.1016/j.jiac.2025.102781

Nationwide surveillance of antibacterial susceptibility in bacterial respiratory pathogens in Japan, 2022-2023

Issei Tokimatsu et al. J Infect Chemother. 2025 Oct.

. 2025 Oct;31(10):102781.

doi: 10.1016/j.jiac.2025.102781. Epub 2025 Aug 6.

Authors

Affiliations

¹ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Showa Medical University School of Medicine, Tokyo, Japan. Electronic address: issei@med.showa-u.ac.jp.
² The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; National Defense Medical College Hospital, Saitama, Japan.
³ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
⁴ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; The Jikei University Kashiwa Hospital, Chiba, Japan.
⁵ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Japanese Red Cross Sendai Hospital, Miyagi, Japan.
⁶ The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Keio University Hospital, Tokyo, Japan.
⁷ MicroSKY Lab, Inc, Tokyo, Japan.
⁸ Asahikawa Medical University Hospital, Hokkaido, Japan.
⁹ Saka General Hospital, Miyagi, Japan.
¹⁰ Kyorin University Hospital, Tokyo, Japan.
¹¹ Keio University Hospital, Tokyo, Japan.
¹² Yokohama City University Medical Center, Kanagawa, Japan.
¹³ The Jikei University Kashiwa Hospital, Chiba, Japan.
¹⁴ Niigata City General Hospital, Niigata, Japan.
¹⁵ Shinrakuen Hospital, Niigata, Japan.
¹⁶ Kanazawa Medical University, Ishikawa, Japan.
¹⁷ Toyama University Hospital, Toyama, Japan.
¹⁸ Aichi Medical University Hospital, Aichi, Japan.
¹⁹ Mie Prefectural Ichishi Hospital, Mie, Japan.
²⁰ Nagoya City University Hospital, Aichi, Japan.
²¹ Osaka City General Hospital, Osaka, Japan.
²² Nara Medical University Hospital, Nara, Japan.
²³ Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
²⁴ Osaka Metropolitan University Hospital, Osaka, Japan.
²⁵ Kindai University Hospital, Osaka, Japan.
²⁶ Kawasaki Medical School Hospital, Okayama, Japan.
²⁷ Matsue Red Cross Hospital, Shimane, Japan.
²⁸ Hospital of the University of the Occupational and Environmental Health, Japan, Fukuoka, Japan.
²⁹ Fukuoka University Hospital, Fukuoka, Japan.
³⁰ Nagasaki University Hospital, Nagasaki, Japan.
³¹ Oita University Hospital, Oita, Japan.
³² Saiseikai Kumamoto Hospital, Kumamoto, Japan.
³³ Nakagami Hospital, Okinawa, Japan.

PMID: 40774506
DOI: 10.1016/j.jiac.2025.102781

Abstract

The emergence and spread of antimicrobial resistant (AMR) have become a major global concern. This nationwide surveillance study, conducted by the Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology from 2022 to 2023, examined the antimicrobial susceptibility of respiratory pathogens. A total of 1057 bacterial isolates from 28 medical institutions, predominantly tertiary medical centers, were analyzed. Major pathogens included Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Findings revealed increasing resistance rates, with a notable rise in extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae. Susceptibility to penicillin, cephalosporins, and carbapenems varied, with specific declines observed in several antibiotics relative to prior surveillance data. No metallo-β-lactamase (MBL)-producing P. aeruginosa strains were detected. These findings underscore the need for rigorous antimicrobial stewardship and continuous surveillance to curb the spread of resistant pathogens in Japan.

Keywords: Antimicrobial resistance; Antimicrobial susceptibility; Bacterial respiratory pathogens; Respiratory tract infection; Surveillance; β-lactamase-producing bacteria.

Copyright © 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Issei Tokimatsu received research funding and scholarship donations from Shionogi & Co., Ltd. and Daiichi Sankyo Co., Ltd. Tetsuya Matsumoto received speaker honoraria from MSD K.K., Pfizer Japan, Inc., Shionogi & Co., Ltd., and Kyorin Pharmaceutical Co., Ltd. Hiroki Tsukada received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Makoto Miki received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Yoshitomo Morinaga received research funding from MSD K.K. and Nichirei Biosciences Inc. Satoshi Takahashi received speaker honoraria from Fujirebio Inc. and MSD K.K., and research funding from Shino-Test Corporation, Roche Diagnostic K. K., Fujirebio Inc., and Abbott Japan Co., Ltd. Naoki Hasegawa received speaker honoraria from Pfizer Japan Inc. Daisuke Kurai received speaker honoraria from GSK, and scholarship donations from Shionogi & Co., Ltd. Satoshi Kawasaki received speaker honoraria from Pfizer Japan, Inc. Yoshitsugu Iinuma received speaker honoraria from MSD K.K. Hiroshige Mikamo received speaker honoraria from Nippon Becton Dickinson Company, Ltd., Sumitomo Pharma Co., Ltd., Pfizer Japan Inc., MSD K.K., Daiichi Sankyo Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., Miyarisan Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co., Ltd., Gilead Sciences K.K., Saraya Co., Ltd., Tsumura & Co., Meiji Seika Pharma Co., Ltd., Shionogi & Co., Ltd., Fukoku Co., Ltd., GlaxoSmithKline K.K., Kowa Company, Ltd., Asahi Kasei Pharma Co., Roche Diagnostics K.K., NIPRO Co., research funding from Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc., Miyarisan Pharmaceutical Co. Ltd., Roche Diagnostics K.K., Kyorin Pharmaceutical Co., Ltd., and scholarship donations from Asahi Kasei Pharma Co., Shionogi & Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., Sumitomo Pharma Co., Ltd., Fukoku Co., Ltd. NIPRO Co., and Tec International Inc. Hiroshi Kakeya received speaker honoraria from MSD K.K., Sumitomo Pharma Co., Ltd., Shionogi & Co., Ltd., Asahi Kasei Pharma Corporation., Kyorin Pharmaceutical Co., Ltd., Pfizer Japan Inc., and GSK K.K. Katsunori Yanagihara received speaker honoraria from Daiichi Sankyo Co., Ltd., MSD K.K., Taisho Pharma Co., Ltd., GSK K.K., Nippon Becton Dickinson Company, Ltd., bioMérieux Japan Ltd., and Abbott Diagnostics Medical Co., Ltd., research funding from Fujifilm Toyama Chemical Co., Ltd., Meiji Seika Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd., and scholarship donations from Fujifilm Toyama Chemical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Tosoh Corporation, and Eiken Chemical Co.,Ltd.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nationwide surveillance of antibacterial susceptibility in bacterial respiratory pathogens in Japan, 2022-2023

Affiliations

Nationwide surveillance of antibacterial susceptibility in bacterial respiratory pathogens in Japan, 2022-2023

Authors

Affiliations

Abstract

Conflict of interest statement

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous